Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Resectable NSCLC
NCT00923949Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pioglitazone in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Aug 2008; status: terminated.
02
Drugs
pioglitazone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00923949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923949.